Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Surgery today 48(4) 431-438 2018

Takeyama H, Beppu T, Higashi T, Kaida T, Arima K, Taki K, Imai K, Nitta H, Hayashi H, Nakagawa S, Okabe H, Hashimoto D, Chikamoto A, Ishiko T, Tanaka M, Sasaki Y, Baba H.

Vonoprazan is superior to rabeprazole for healing endoscopic submucosal dissection induced ulcers.

Digestion 97:170-176, 2018

Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y and Fujisaki J.

The Incidence of Complications in Single-stage Endoscopic Stone Removal for Patients with Common Bile Duct Stones: A Propensity Score Analysis.

Intern Med. 2018; 57(4): 469-477

Saito H, Kadono Y, Kamikawa K, Urata A, Imamura H, Matsushita I, Kakuma T, Tada S.

Usefullness and limitations of dual-layer spectral detector computed tomography for diagnosing biliary stones not detected by conventional computed tomography: a report of three cases.

Clin J Gastroenterol. 2018; 11(2): 172-177

Saito H, Noda K, Ogasawara K, Atsuji S, Takaoka H, Kajihara H, Nasu J, Morishita S, Matsushita I, Katahira K.

Reduced iodinated contrast media for abdominal imaging by dual-layer spectral detector computed tomography for patients with kidney disease.

Radiol Case Rep. 2018 13(2): 437-443

Saito H, Noda K, Ogasawara K, Atsuji S, Takaoka H, Kajihara H, Nasu J, Kitaoka M, Morishita S, Matsushita I, Katahira K.

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The lancet.

Gastroenterology & hepatology 3(6) 424-432 2018

Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, SILIUS study group.

Analysis for the primary predictive factor for the incidence of esophageal injury after ablation of atrial fibrillation.

J Cardiol. 2018 Dec;72(6):480-487.

Ito M, Yamabe H, Koyama J, Kanazawa H, Kaneko S, Kanemaru Y, Kiyama T, Arima Y, Takashio S, Yamamoto E, Izumiya Y, Kojima S, Kaikita K, Shono T, Utsunomiya D, Sasaki Y, Yamashita Y, Tsujita K.

Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.

Drug Deliv. 2018 Nov;25(1):1067-1077.

Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T.

Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer.

In Vivo. 2018 Nov-Dec;32(6):1519-1525.

Saito T, Toya R, Yoshida N, Shono T, Matsuyama T, Ninomura S, Watakabe T, Sasaki Y, Baba H, Oya N.

Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.

Oncol Lett. 2018 Oct;16(4):5275-5281.

Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H.

Impact of retroflexion in the right colon after repeated forward-view examination.

JGH Open. 2018 Sep 10;2(6):282-287.

Miyamoto H, Naoe H, Oda Y, Shono T, Narita R, Oyama S, Hashigo S, Okuda A, Hasuda K, Tanaka M, Sakurai K, Murakami Y, Sasaki Y.

Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.

Cancer Lett. 2018 Aug 10; 429:1-10.

Huang CK,Iwagami Y,Aou J,Casulli S,Lu S,Nagaoka K,Ji C,Ogawa K,Cao KY,Gao JS,Carlson RI,Wandas JR.

Usefulness of Virtual Touch Quantification for Staging Liver Fibrosis in Patients with Hepatitis C, and Factors Affecting Liver Stiffness Measurement Failure Compared with Liver Biopsy.

Hepatol Res. Apr; 48(5):373-382, 2018

Tsukano N, Miyase S, Saeki T, Mizobe K, Iwashita H, Arima N, Fujiyama S.

Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomized, open label, phase 3 trial.

The Lancet Gastroenterology Hepatology. 2018 Jun; 3(6): 424-432

Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura K, Arai Y, the SILIUS study group.

LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation.

Nucleic Acids Res. 2018 Jun 20; 46(11):5441-5454.

Anan K, Hino S, Shimizu N, Sakamoto A, Nagaoka K, Takase R, Kohrogi K, Araki H, Hino Y, Usuki S, Oki S, Tanaka H, Nakamura K, Endo F, Nakao M.

Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.

CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):384-393.

Oniki K, Watanabe T, Kudo M, Izuka T, Ono T, Matsuda K, Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y, Watanabe H, Maruyama T, Otake K, Ogata Y, Saruwatari J.

Impact of retroflexion in the right colon after repeated forward-view examinations.

JGH open　2/P.282-287/2018

Miyamoto H, Naoe H, Oda Y, Shono T, Narita R, Oyama S, Hashigo S, Okuda A, Hasuda K, Tanaka M, Sakurai K, Murakami Y, Sasaki Y

Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver

Transplant Proc　50/P.3858-3862/2018

Harimoto N, Nakagawara H, Shirabe K, Yoshizumi T, Itoh S, Ikegami T, Soejima Y, Maehara Y, Ishida Y, Tateno C, Tanaka Y

Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C.

Open Forum Infect Dis　5/P.ofy268-/2018

Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, Toyoda H, Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.

Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B

Aliment Pharmacol Ther　48/P.1128-1137/2018

Hsu Y-C, Jun T, Huang Y-T, Yeh M-L, Lee C-L, Ogawa S, Cho S-H, Lin J-T, Yu M-L, Nguyen MH, Tanaka Y

Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.

Oncol Lett　16/P.5275-5281/2018

Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H.

Type I interferon signaling prevents hepatitis B virus-specific T cell responses by reducing antigen expression

J Virol　92/P.e01099-/2018

Kawashima K, Isogawa M, Hamada-Tsutsumi S, Baudi I, Saito S, Nakajima A, Tanaka Y

Intrahepatic Cross-Presentation and Hepatocellular Antigen Presentation Play Distinct Roles in the Induction of Hepatitis B Virus-Specific CD8 + T Cell Responses

J Virol　92/P.e00920-/2018

Murata Y, Kawashima K, Sheikh K, Tanaka Y, Isogawa M

Screening of microRNAs for a repressor of hepatitis B virus replication

Oncotarget　9/P.29857-29868/2018

Naito Y, Hamada-Tsutsumi S, Yamamoto Y, Kogure A, Yoshioka Y, Watashi K, Ochiya T, Tanaka Y

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

Hepatol Int　12/P.356-367/2018

Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M

Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment.

Cancer Lett　434/P.91-100/2018

Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, Takeba Y, Otsubo T, Takagi M, Ariizumi Y, Suzuki M, Okuse C, Iwabuchi S, Nakano M, Akutsu N, Kang J-H, Matsui T, Yamada N, Sasaki H, Yamamoto E, Kai M, Sasaki Y, Sasaki S, Tanaka Y, Yotsuyanagi H, Tsutsumi T, Yamamoto H, Tokino T, Nakase H, Suzuki H, Itoh F

Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer

Hepatol Res　48/P.1081-1091/2018

Izumida K, Kaneko A, Takahashi K, Kusumoto S, Narita T, Takami A, Iida S, Aoyagi K, Tanaka Y

Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infection

Hepatol Res　48/P.1172-1177/2018

Tajiri H, Takano T, Tanaka Y, Murakami J, Brooks S

De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry

Cell Chem Biol　25/P.906-915. e7/2018

Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T

Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells

Mol Ther　26/P.1840-1854/2018

Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T

Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan

J Gastroenterol　53/P.1276-1284/2018

Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T

Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma

Hepatol Res　48/P.872-881/2018

Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, Tangkijvanich P

Gut dysbiosis associated with hepatitis C virus infection

Clin Infect Dis　67/P.869-877/2018

Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y

Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

Hepatol Int　12/P.133-142/2018

Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K

Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.

CPT Pharmacometrics Syst Pharmacol　7/P.384-393/2018

Oniki K, Watanabe T, Kudo M,Izuka T, Ono T, Matsuda K,Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y,Watanabe H, Maruyama T, Otake K,Ogata Y, Saruwatari J

Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

Hepatol Res　48/P.549-555/2018

Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K

Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers

Digestion　97/P.170-176/2018

Yamasaki A, Yoshio　T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y,　Fujisaki J

High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues

J Gastroenterol　53/P.883-889/2018

Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y

Antiviral therapy for hepatitis B virus during second pregnancies

J Obstet Gynaecol Res　44/P.566-569/2018

Wakano Y, Sugiura T, Endo T, Ito K, Suzuki M, Tajiri H, Tanaka Y, Saitoh S

Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis c virus genotype 1b infection with liver cirrhosis

Intern Med　57/P.951-956/2018

Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W

Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus

Hepatol Res　48/P.E203-E212/2018

Inoue T, Goto T, Iio E, Matsunami K, Fujiwara K, Shinkai N, Matsuura K, Matsui T, Nojiri S, Tanaka Y

Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon–based therapy

Clin Microbiol Infect　24/P.306. e7-306. e13/2018

Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P

Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease

J Gastroenterol　53/P.438-448/2018

Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y

Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

J Gastroenterol　53/P.247-257/2018

Matsumoto A, Nishiguchi S, Enomoto H, Kang J-H, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan

J Gastroenterol　53/P.119-128/2018

Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N

Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients

Hepatol Res　48/P.134-143/2018

Shen S, Liang X, Hamed K, Tanaka Y, Omagari K, Fan R, Xie Q, Tan D, Zhou B, Jia J-D, Hou J, Sun J